MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03845nam a22005655i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20231109085800.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220512s2022 sz | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9783030963767 |
| 024 7# - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/978-3-030-96376-7 |
| Source of number or code |
doi |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
TR-AnTOB |
| Language of cataloging |
eng |
| Transcribing agency |
TR-AnTOB |
| Description conventions |
rda |
| 060 #4 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
QZ 266 |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MJCL |
| Source |
bicssc |
|
|---|
| Subject category code |
MED062000 |
| Source |
bisacsh |
|
|---|
| Subject category code |
MJCL |
| Source |
thema |
| 096 ## - LOCALLY ASSIGNED NLM-TYPE CALL NUMBER (OCLC) |
|---|
| Classification number |
QZ266EBK |
| 041 ## - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
İngilizce |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Cancer Immunotherapies |
| Medium |
[electronic resource] : |
| Remainder of title |
Solid Tumors and Hematologic Malignancies / |
| Statement of responsibility, etc. |
edited by Priya Hays. |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
1st ed. 2022. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Cham : |
| Name of producer, publisher, distributor, manufacturer |
Springer International Publishing : |
| -- |
Imprint: Springer, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2022. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 online resource |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| Source |
rdacarrier |
| 347 ## - DIGITAL FILE CHARACTERISTICS |
|---|
| File type |
text file |
| Encoding format |
PDF |
| Source |
rda |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Cancer Treatment and Research, |
| International Standard Serial Number |
2509-8497 ; |
| Volume/sequential designation |
183 |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Development of Cancer Immunotherapies -- Melanoma -- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity -- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer -- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma -- Lag3: From Bench to Bedside -- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution -- Immune-based therapeutic interventions for Acute Myeloid Leukemia.-Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells -- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells -- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Oncology. |
|
|---|
| Topical term or geographic name entry element |
Hematology. |
|
|---|
| Topical term or geographic name entry element |
Genetics. |
|
|---|
| Topical term or geographic name entry element |
Genomics. |
|
|---|
| Topical term or geographic name entry element |
Oncology. |
|
|---|
| Topical term or geographic name entry element |
Hematology. |
|
|---|
| Topical term or geographic name entry element |
Genetics. |
|
|---|
| Topical term or geographic name entry element |
Genomics. |
| 653 #0 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Neoplasms -- immunology |
|
|---|
| Uncontrolled term |
Neoplasms -- therapy |
|
|---|
| Uncontrolled term |
Immunotherapy |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Hays, Priya. |
| Relator term |
editor. |
| Relator code |
edt |
| -- |
http://id.loc.gov/vocabulary/relators/edt |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Cancer Treatment and Research, |
| International Standard Serial Number |
2509-8497 ; |
| Volume/sequential designation |
183 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="https://doi.org/10.1007/978-3-030-96376-7">https://doi.org/10.1007/978-3-030-96376-7</a> |
| Materials specified |
Springer eBooks |
| Public note |
Online access link to the resource |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
National Library of Medicine |
| Koha item type |
E-Book |
